Author's response to reviews

Title: Effects of Korean Red Ginseng (Panax Ginseng Meyer) on Bisphenol A Exposure and Gynecologic Complaints: Single blind, randomized clinical trial of efficacy and safety

Authors:

Mihi Yang (myang@sm.ac.kr)
Min-Woo Hwang (azure92@daum.net)
Mirim Jin (mirimj@dju.kr)
Eun Cho (eun-cho@sookmyung.ac.kr)

Version: 6 Date: 23 June 2014

Author's response to reviews: see over
RE: Effects of Korean Red Ginseng (Panax Ginseng Meyer) on Bisphenol A Exposure and Gynecologic Complaints:
Single blind, randomized clinical trial of efficacy and safety

Dear Dr. Tom Rowles, BMC Complementary & Alternative Medicine,

I would like to submit our 2nd-revised manuscript. I appreciate the reviewers’ effort for comments and believe they improve our manuscript.

Please let me answer with a point by point description of the changes made.

Reviewer1:

Minor comment;

Because one BPA outlier in control group in Figure 4 seems to affect results of KRG assay significantly, The author may consider to mention in the limitation section.
Answer) Following the comment, we added limitation of the number of subjects in bottom of page 15.

Reviewer 2:
- Major Compulsory Revisions
  1. The authors should explain the scientific evidence why 2.7 g/day of KRG has been determined as administration dosage. (For example, in vivo or clinical trials)
Answer) There are various doses of KRG for different health outcomes in clinical trials. For example, low dose (3 g) and high dose (6 g) of the KRG were used for oxidative stress [1]. For sexual arousal, 3 g of KRG was used among menopausal women [2]. In addition, the manufacturer suggested maximum 2.7 g of KRG power (=9 capsules) /day for safety [2]. Taken together, we decided 2.7 g of KRG for the present study. We added the above background for dosage on page 6 in the
method section.

- Minor Essential Revisions

1. The difference between group presented Fig 5.
   Answer) We revised fig 5 with relative comparison between the two groups, i.e. KRG and placebo. We also added it on head of page 12 in the result part.

We sincerely hope our second revised version satisfies the reviewers’ comments for publication.

Yours sincerely,
Professor Mihi Yang, Ph. D. & D.A.B.T.
Department of Toxicology
Research Center for Cell Fate Control
College of Pharmacy, Sookmyung Women's University
Cheongpa-ro 47-gil 100, Yongsan-gu, Seoul, 140-742, Republic of Korea
Tel. 82-2-2077-7179 / Fax. 82-2-710-9871 E-mail. myang@sookmyung.ac.kr

References